Business Context and Reporting Period
Company: Biospherics Incorporated (trading as "Spherix" starting Jan 2001; ticker BINC, changing to SPEX).
Reporting Period: Fiscal year ended December 31, 2000.
Business Segments: The Company operates two primary segments: InfoSpherix (Commercial and Government Information Services, plus IT services) and BioSpherix (Biotechnology R&D). InfoSpherix generated 99% of total revenue in 2000.
Key Operations: InfoSpherix provides data management, clinical trial support, and reservation systems (notably for the U.S. Government and Michigan Dept. of Natural Resources). BioSpherix focuses on tagatose (a low-calorie sweetener licensed to Arla Foods) and "FlyCracker" (a safe pesticide).
Key Financial Metrics (Year Ended Dec 31, 2000)
| Metric | 2000 | 1999 |
|---|---|---|
| Total Revenue | $17,034,694 | $12,698,412 |
| Net Income (Loss) | $591,070 | $(5,205,097) |
| EPS (Diluted) | $0.06 | $(0.55) |
| Operating Income | $411,047 | $(4,693,721) |
| Operating Margin | 2.4% | (36.9%) |
| Cash & Equivalents | $5,549,866 | $1,437,280 |
| Working Capital | $6,357,594 | $60,899 |
| Long-Term Debt | $358,411 | $1,490,765 |
| Bank Line of Credit (Outstanding) | $386,274 | $1,277,853 |
| Operating Cash Flow | $1,697,244 | $(1,106,578) |
Material Changes vs. Prior Period
- Profitability Turnaround: The Company returned to profitability in 2000 ($591k net income) compared to a significant loss in 1999 ($5.2M). This was driven by a 34% revenue increase and the absence of the $2.0M asset write-down recorded in 1999.
- Revenue Growth: Total revenue increased by $4.3M (34%). InfoSpherix revenue grew $4.3M, driven by new commercial and government contracts. BioSpherix revenue increased slightly by $20k.
- Liquidity Improvement: Working capital surged from $61k to $6.4M, primarily due to a $5M private placement of stock in February 2000 and profitable operations.
- Debt Reduction: Long-term debt obligations decreased by approximately $1.1M as the Company paid down notes and utilized cash reserves.
- Contract Mix: The Federal Information Center (FIC) contract ended in Oct 2000 (contributing $2.7M revenue), but was offset by a new 3-year, $9.5M contract with the Michigan Department of Natural Resources.
Guidance, Outlook, and Risks
- Outlook: Management anticipates revenue loss from the expired FIC contract will be offset by the new Michigan contract starting in Q1 2001. The Company expects sufficient cash flow from operations to cover capital needs in 2001.
- BioSpherix Catalysts: Commercialization of tagatose depends on FDA "GRAS" (Generally Recognized As Safe) status, expected early 2001. Arla Foods (licensee) is constructing a commercial plant pending this approval. FlyCracker pesticide received OMRI approval for organic use in Jan 2001.
- Customer Concentration Risk: The Company relies heavily on a few large contracts. In 2000, the U.S. Government, Pfizer, and McKesson HBOC-PPG each accounted for >10% of revenue. Future revenue is expected to be similarly concentrated with the U.S. Government, State of Michigan, and State of Maryland.
- Accounting Change: The Company changed independent auditors from PricewaterhouseCoopers LLP to Grant Thornton LLP in April 2000. No disagreements were reported regarding accounting principles.
- Forward-Looking Statements: The filing includes standard disclaimers regarding risks that could cause actual results to differ, including regulatory approvals for tagatose and the success of new contract negotiations.
Investor Verification Checklist
- Tagatose Regulatory Status: Verify the timeline for FDA GRAS approval and Arla Foods' plant construction progress, as this is the primary long-term growth driver for BioSpherix.
- Contract Renewals: Monitor the execution of the new Michigan Department of Natural Resources contract and the renewal of the Bank of America line of credit (expires June 30, 2001).
- Customer Concentration: Assess the risk associated with the top 3-4 customers representing the majority of revenue; loss of a single government contract could materially impact results.
- Stock Dilution: Review the impact of outstanding warrants (approx. 1.66M shares) and the 9.9% ownership cap held by the institutional investor from the 2000 private placement.
- Asset Valuation: Confirm that no further write-downs of capitalized software or technology assets are necessary, given the $2M write-down in 1999.